"Pharmacogenomic Testing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The detection of genetic variability (e.g., PHARMACOGENOMIC VARIANTS) relevant to PHARMACOGENETICS and PRECISION MEDICINE. The purpose of such genetic testing is to help determine the most effective treatment options and their optimum dosages with least potential risks for DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS.
| Descriptor ID |
D000071185
|
| MeSH Number(s) |
E01.370.225.562.500 E05.200.562.500 E05.393.435.500 N02.421.308.430.500 N02.421.726.233.221.500
|
| Concept/Terms |
Pharmacogenomic Testing- Pharmacogenomic Testing
- Pharmacogenomic Testings
- Pharmacogenomic Screening
- Pharmacogenomic Screenings
- Pharmacogenetic Screening
- Pharmacogenetic Screenings
- Pharmacogenetic Testing
- Pharmacogenetic Testings
Pharmacogenomic Analysis- Pharmacogenomic Analysis
- Pharmacogenomic Analyses
- Pharmacogenetic Study
- Pharmacogenetic Studies
- Studies, Pharmacogenetic
- Pharmacogenetic Analysis
- Pharmacogenetic Analyses
- Pharmacogenomic Study
- Pharmacogenomic Studies
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Testing".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Testing".
This graph shows the total number of publications written about "Pharmacogenomic Testing" by people in this website by year, and whether "Pharmacogenomic Testing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 2 | 3 |
| 2017 | 4 | 2 | 6 |
| 2018 | 2 | 1 | 3 |
| 2019 | 4 | 4 | 8 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 2 | 4 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 3 | 2 | 5 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenomic Testing" by people in Profiles.
-
Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation. Clin Transl Sci. 2026 04; 19(4):e70537.
-
Pharmacogenomic Testing for CYP2C19 Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory? J Appl Lab Med. 2025 Jul 01; 10(4):976-982.
-
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. Clin Pharmacol Ther. 2025 10; 118(4):906-916.
-
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges. Clin Pharmacol Ther. 2025 Oct; 118(4):778-789.
-
Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing. Clin Transl Sci. 2025 04; 18(4):e70193.
-
A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic Information. Clin Pharmacol Ther. 2025 06; 117(6):1793-1802.
-
Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression. Clin Transl Sci. 2024 06; 17(6):e13822.
-
A pilot pharmacogenetic study of calcium channel blocker treatment of bipolar mania. Psychiatry Res. 2023 08; 326:115281.
-
Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
-
Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. Cardiovasc Drugs Ther. 2024 06; 38(3):447-457.